276 related articles for article (PubMed ID: 32051841)
1. Keloid pathophysiology: fibroblast or inflammatory disorders?
Nangole FW; Agak GW
JPRAS Open; 2019 Dec; 22():44-54. PubMed ID: 32051841
[TBL] [Abstract][Full Text] [Related]
2. The Keloid Disorder: Heterogeneity, Histopathology, Mechanisms and Models.
Limandjaja GC; Niessen FB; Scheper RJ; Gibbs S
Front Cell Dev Biol; 2020; 8():360. PubMed ID: 32528951
[TBL] [Abstract][Full Text] [Related]
3. The Communication from Immune Cells to the Fibroblasts in Keloids: Implications for Immunotherapy.
Zhang X; Wu X; Li D
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895153
[TBL] [Abstract][Full Text] [Related]
4. Premature collagen fibril formation, fibroblast-mast cell interactions and mast cell-mediated phagocytosis of collagen in keloids.
Arbi S; Eksteen EC; Oberholzer HM; Taute H; Bester MJ
Ultrastruct Pathol; 2015 Apr; 39(2):95-103. PubMed ID: 25569098
[TBL] [Abstract][Full Text] [Related]
5. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis - Keloids and hypertrophic scars may be vascular disorders.
Ogawa R; Akaishi S
Med Hypotheses; 2016 Nov; 96():51-60. PubMed ID: 27959277
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of inhibitory SMAD6 and SMAD7 in keloid scarring.
Yu H; Bock O; Bayat A; Ferguson MW; Mrowietz U
J Plast Reconstr Aesthet Surg; 2006; 59(3):221-9. PubMed ID: 16676428
[TBL] [Abstract][Full Text] [Related]
7. Studies of transforming growth factors beta 1-3 and their receptors I and II in fibroblast of keloids and hypertrophic scars.
Bock O; Yu H; Zitron S; Bayat A; Ferguson MW; Mrowietz U
Acta Derm Venereol; 2005; 85(3):216-20. PubMed ID: 16040405
[TBL] [Abstract][Full Text] [Related]
8. FK506 inhibits the enhancing effects of transforming growth factor (TGF)-β1 on collagen expression and TGF-β/Smad signalling in keloid fibroblasts: implication for new therapeutic approach.
Wu CS; Wu PH; Fang AH; Lan CC
Br J Dermatol; 2012 Sep; 167(3):532-41. PubMed ID: 22540338
[TBL] [Abstract][Full Text] [Related]
9. Involvement of upper torso stress amplification, tissue compression and distortion in the pathogenesis of keloids.
Bux S; Madaree A
Med Hypotheses; 2012 Mar; 78(3):356-63. PubMed ID: 22230168
[TBL] [Abstract][Full Text] [Related]
10. Effect of the abrogation of TGF-beta1 by antisense oligonucleotides on the expression of TGF-beta-isoforms and their receptors I and II in isolated fibroblasts from keloid scars.
Bran GM; Goessler UR; Schardt C; Hormann K; Riedel F; Sadick H
Int J Mol Med; 2010 Jun; 25(6):915-21. PubMed ID: 20428796
[TBL] [Abstract][Full Text] [Related]
11. Telomere shortening may be associated with human keloids.
De Felice B; Wilson RR; Nacca M
BMC Med Genet; 2009 Oct; 10():110. PubMed ID: 19863817
[TBL] [Abstract][Full Text] [Related]
12. Single-Cell RNA-Sequencing Reveals Lineage-Specific Regulatory Changes of Fibroblasts and Vascular Endothelial Cells in Keloids.
Liu X; Chen W; Zeng Q; Ma B; Li Z; Meng T; Chen J; Yu N; Zhou Z; Long X
J Invest Dermatol; 2022 Jan; 142(1):124-135.e11. PubMed ID: 34242659
[TBL] [Abstract][Full Text] [Related]
13. Keloids: The paradigm of skin fibrosis - Pathomechanisms and treatment.
Andrews JP; Marttala J; Macarak E; Rosenbloom J; Uitto J
Matrix Biol; 2016 Apr; 51():37-46. PubMed ID: 26844756
[TBL] [Abstract][Full Text] [Related]
14. Growth Differentiation Factor-9 Promotes Fibroblast Proliferation and Migration in Keloids through the Smad2/3 Pathway.
Jiang Z; Yu Q; Xia L; Zhang Y; Wang X; Wu X; Gao Z
Cell Physiol Biochem; 2016; 40(1-2):207-218. PubMed ID: 27855376
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option.
Dienus K; Bayat A; Gilmore BF; Seifert O
Arch Dermatol Res; 2010 Dec; 302(10):725-31. PubMed ID: 20872224
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin A for the treatment of keloids.
Gauglitz GG; Bureik D; Dombrowski Y; Pavicic T; Ruzicka T; Schauber J
Skin Pharmacol Physiol; 2012; 25(6):313-8. PubMed ID: 22948093
[TBL] [Abstract][Full Text] [Related]
17. Biomechanical Regulatory Factors and Therapeutic Targets in Keloid Fibrosis.
Feng F; Liu M; Pan L; Wu J; Wang C; Yang L; Liu W; Xu W; Lei M
Front Pharmacol; 2022; 13():906212. PubMed ID: 35614943
[TBL] [Abstract][Full Text] [Related]
18. Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids.
Lee TY; Chin GS; Kim WJ; Chau D; Gittes GK; Longaker MT
Ann Plast Surg; 1999 Aug; 43(2):179-84. PubMed ID: 10454326
[TBL] [Abstract][Full Text] [Related]
19. Collagen triple helix repeat containing-1 inhibits transforming growth factor-b1-induced collagen type I expression in keloid.
Li J; Cao J; Li M; Yu Y; Yang Y; Xiao X; Wu Z; Wang L; Tu Y; Chen H
Br J Dermatol; 2011 May; 164(5):1030-6. PubMed ID: 21667528
[TBL] [Abstract][Full Text] [Related]
20. Effect of tamoxifen on transforming growth factor beta1 production by keloid and fetal fibroblasts.
Mikulec AA; Hanasono MM; Lum J; Kadleck JM; Kita M; Koch RJ
Arch Facial Plast Surg; 2001; 3(2):111-4. PubMed ID: 11368663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
